STA Wealth Management LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 240.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,823 shares of the company’s stock after acquiring an additional 7,648 shares during the period. Johnson & Johnson comprises approximately 0.4% of STA Wealth Management LLC’s holdings, making the stock its 27th biggest holding. STA Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,507,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of the company. Virtus ETF Advisers LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $25,000. Krane Funds Advisors LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at $26,000. Crewe Advisors LLC grew its holdings in Johnson & Johnson by 725.9% during the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares in the last quarter. Permanens Capital L.P. grew its holdings in Johnson & Johnson by 50.0% during the 2nd quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock valued at $42,000 after purchasing an additional 100 shares in the last quarter. Finally, Evolution Wealth Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter worth $40,000. 72.01% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE JNJ traded up $0.36 during midday trading on Wednesday, hitting $130.03. The company’s stock had a trading volume of 2,436,537 shares, compared to its average volume of 7,500,207. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The firm’s fifty day moving average price is $130.10 and its 200-day moving average price is $135.82. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm has a market cap of $345.15 billion, a P/E ratio of 15.90, a P/E/G ratio of 2.21 and a beta of 0.68.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The business had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period in the previous year, the business posted $2.10 EPS. The company’s quarterly revenue was down 1.3% on a year-over-year basis. As a group, research analysts predict that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.92%. The ex-dividend date of this dividend was Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Several research analysts have weighed in on the stock. Morgan Stanley reissued an “equal weight” rating and set a $145.00 price objective on shares of Johnson & Johnson in a report on Tuesday, August 27th. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Bank of America reissued a “hold” rating and set a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Finally, Barclays assumed coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price objective for the company. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $150.60.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.